How much funding has SciNeuro raised?

SciNeuro has raised $153.0M in total funding, most recently a Series B round.

Where is SciNeuro headquartered?

SciNeuro is headquartered in Shanghai, China.

What industry is SciNeuro in?

SciNeuro operates in Life Sciences.

SciNeuro

Q: Who are SciNeuro's investors?

SciNeuro's investors include Lilly Asia Ventures, ARCH Venture Partners, General Atlantic.

Deciphering the Enigma of Brain Disease

Shanghai, China · Founded 2020 · $153.0M raised

Life Sciences

Headquarters: Shanghai
Founded: 2020
Business Model: B2B
Website: scineuro.com

Total Funding: $153.0M
Last Round: $53.0M Series BDec 2025
Rounds: 2

About

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company transforming scientific discoveries into therapies for central nervous system diseases, with an expert team spanning discovery to clinical development in the US and China. Founded in late 2020 by Dr. Min Li, the company's pipeline addresses neurovascular inflammation, proteinopathy, and immune-driven neurodegeneration, including a blood-brain-barrier shuttle platform for CNS drug delivery. SciNeuro licensed a next-generation anti-amyloid antibody to Novartis for $165 million upfront and up to $1.5 billion in milestones, and separately raised $53 million to advance its pipeline.

Summary

SciNeuro is a Life Sciences company based in Shanghai, China, founded in 2020. It has raised $153.0M in total across 2 rounds, most recently a $53.0M Series B round in Dec 2025. Investors include Lilly Asia Ventures, ARCH Venture Partners and General Atlantic.